JDBIO Successfully Completes Participation in InterCHARM KOREA 2026
JDBIO Co., Ltd. (JDBIO), a global beauty and medical group, successfully completed its participation in the global beauty and cosmetics exhibition “InterCHARM KOREA 2026,” held at COEX in Seoul.
During the exhibition, held from July 1 to 3, JDBIO prepared a large-scale independent booth and presented a wide range of its core aesthetic portfolio proven in global markets, receiving considerable interest from buyers and medical professionals from around the world.
The exhibition space was presented in a diverse manner, featuring a showcase where visitors could view JDBIO’s major product lineup at a glance, a Photo Wall event space where visitors could directly participate and experience the event, and the premium ‘DR. RICHESSE CAFÉ’ lounge for visitors.
The main products exhibited included the company’s representative solution, ‘RICHESSE™ Filler’; the botulinum toxin products ‘OneTox’ and ‘Red Tox’, which have secured stability through highly purified technologies; the high-purity HA body fillers ‘DEMEI™ BODY 60/100’; and the premium skin booster ‘RICHESSE™ TRINITY90 with RH’, based on RH collagen, HA and Vitamin B Complex. In addition, the high-functional skincare line ‘DR. RICHESSE’ was also exhibited, receiving a strong response from visitors at the venue.
In particular, JDBIO broadened its interaction with visitors through a customer-participation photo zone event featuring cute ‘RedTox’ character pickets, while also introducing its next-generation skin booster solutions. In addition, the company held successful business meetings with representatives of global distributors through its professional consulting area, achieving results in expanding its networks across the China region and global markets.
A representative of JDBIO Co., Ltd. stated, “Through our participation in InterCHARM KOREA 2026, we were able to once again make JDBIO’s strong brand presence and technological capabilities known in both domestic and international markets. Going forward, we will continue to lead trends in the medical aesthetics market through continuous R&D innovation and the expansion of our global network.”